

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

August 27, 2021

Thomas Freeburg Chief Financial Officer Interpace Biosciences, Inc. Morris Corporate Center 1, Building C 300 Interpace Parkway Parsippany, NJ 07054

> Re: Interpace Biosciences, Inc. Form 10-K for the Fiscal Year Ended December 31, 2020 Filed April 1, 2021 File No. 000-24249

Dear Mr. Freeburg:

We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance Office of Life Sciences